Multiple switches between infliximab originator and biosimilars in pediatric inflammatory bowel disease
Authors:
- 12 June 2026
- journal article
- research article
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 83 (3) , 447-455
Abstract
Objectives: Infliximab (IFX) is highly effective but costly, driving the adoption of biosimilars. Data on switching from originator IFX to biosimilars in pediatric inflammatory bowel disease (IBD) patients remain limited. This study evaluated the safety and efficacy of switching from originator IFX to IFX biosimilar CT‐P13 in IBD. Methods: In this single‐center observational study, we investigated all pediatric patients with IBD on maintenance IFX therapy who were switched from originator (Remicade®) to CT‐P13 (Inflectra®, switch A in cohort A) in 2018 and to CT‐P13 (Remsima®, switch B in cohort B) in 2022. Cohort C includes patients who underwent both switches. Demographics, disease activity, remission rates and IFX trough levels were collected from 6 months before to 6 months after each switch. Results: A total of 42 children (cohort A) and 44 children (cohort B) had a single switch to CT‐P13; 14 (cohort C) had multiple switches. Median IFX trough concentration was 5.7 ([3.8–9.3) and 9.0 (6.2–11.7) µg/mL versus 6.5 (3.9–8.6) and 9.22 (7.9–10.5) µg/mL 6 months after switch in cohort A and B and 4.3 (3.4–10.9) versus 7.9 (6.9–9.7) and 9.3 (8.3–10.3) versus 9.4 (7.9–10.6) for respectively both switches in cohort C (all p > 0.05). Antibodies to IFX developed in one patient post‐switch. Clinical/biological remission rates remained stable. No clinically significant changes in inflammatory biomarkers and safety profile were noted before and after switch. Conclusions: Switching to CT‐P13 biosimilars appears to maintain remission without relevant changes in pharmacokinetics, disease activity, or adverse events in pediatric patients with IBD. Further studies are required.Keywords
This publication has 41 references indexed in Scilit:
- Effectiveness and safety of biosimilars in pediatric inflammatory bowel diseases: an observational longitudinal study on the French National Health Data SystemWorld Journal of Pediatrics, 2025
- Change from originator infliximab to biosimilar does not affect 1‐year outcome in children with inflammatory bowel diseaseJPGN Reports, 2024
- Clinical outcomes and cost savings of a nonmedical switch to a biosimilar in children/young adults with inflammatory bowel diseaseJournal of Pediatric Gastroenterology and Nutrition, 2024
- Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohortUnited European Gastroenterology Journal, 2023
- Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to RemicadeClinical Gastroenterology and Hepatology, 2019
- Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trialThe Lancet, 2017
- Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel DiseaseGastroenterology, 2015
- Pediatric modification of the Montreal classification for inflammatory bowel diseaseInflammatory Bowel Diseases, 2011
- Appraisal of the Pediatric Crohn's Disease Activity Index on Four Prospectively Collected Datasets: Recommended Cutoff Values and Clinimetric PropertiesAmerican Journal of Gastroenterology, 2010
- Development, Validation, and Evaluation of a Pediatric Ulcerative Colitis Activity Index: A Prospective Multicenter StudyGastroenterology, 2007